Impact of Adherence to Antihypertensive Agents on Clinical Outcomes and Hospitalization Costs
- A. Dragomir, R. Cote, S. Perreault
- Medicine, Political ScienceMedical Care
- 1 May 2010
Low adherence to AH agents is correlated with a higher risk of vascular events, hospitalization, and greater healthcare costs, and an increased level of adherence should provide a better health status for individuals and a net economic gain.
Intraoperative floppy‐iris syndrome associated with α1‐adrenoreceptors: Comparison of tamsulosin and alfuzosin
- Marie C. Blouin, J. Blouin, S. Perreault, A. Lapointe, A. Dragomir
- MedicineJournal of cataract and refractive surgery
- 1 July 2007
Persistence and determinants of statin therapy among middle-aged patients for primary and secondary prevention.
- S. Perreault, L. Blais, J. Collin
- MedicineBritish Journal of Clinical Pharmacology
- 1 May 2005
Overall persistence with statins is low, and particularly among patients with few other cardiovascular risk factors, especially among patients who have used the greatest number of pharmacies and prescribing physicians.
Persistence with treatment in newly treated middle-aged patients with essential hypertension.
- S. Perreault, D. Lamarre, J. Collin
- MedicineThe Annals of Pharmacotherapy
- 2 August 2005
Barriers to persistence occur early in the course of therapy, and adherence continues to decline over a period of 3 years, as well as during a one-year period of follow-up.
Effect of statin adherence on cerebrovascular disease in primary prevention.
- S. Perreault, Laura Ellia, L. Lalonde
- MedicineAmerican Journal of Medicine
- 1 July 2009
Drug costs in the management of metastatic castration-resistant prostate cancer in Canada
- A. Dragomir, D. Dinea, M. Vanhuyse, F. Cury, A. Aprikian
- Medicine, Political ScienceBMC Health Services Research
- 13 June 2014
The mean cost of mCRPC drug treatments over an average period of 28.1 months was estimated at $48,428 per patient, and the mean cost increased to $104,071 when one includes abiraterone initiation prior to docetaxel therapy, which may potentially increase the cost.
Impact of adherence to statins on chronic heart failure in primary prevention.
- S. Perreault, A. Dragomir, L. Blais, A. Bérard, L. Lalonde, M. White
- MedicineBritish Journal of Clinical Pharmacology
- 1 November 2008
It is indicated that better adherence to statins is associated with a reduced risk of CHF, and a nested case-control design was used to study CHF.
Long Circulating Poly(Ethylene Glycol)-Decorated Lipid Nanocapsules Deliver Docetaxel to Solid Tumors
- M. Khalid, P. Simard, D. Hoarau, A. Dragomir, J. Leroux
- Biology, ChemistryPharmaceutical Research
- 24 March 2006
This study demonstrates that docetaxel physically entrapped into a lipid colloidal drug carrier can be efficiently targeted to neoplastic tissues.
Impact of a Better Adherence to Antihypertensive Agents on Cerebrovascular Disease for Primary Prevention
- Fatima-Zohra Kettani, A. Dragomir, S. Perreault
- MedicineStroke
- 1 January 2009
High adherence to antihypertensive drugs is associated with a reduced risk of CD outside the context of clinical trials in primary prevention.
Impact of adherence to statins on coronary artery disease in primary prevention.
- Marie-Hélène Bouchard, A. Dragomir, L. Blais, A. Bérard, D. Pilon, S. Perreault
- MedicineBritish Journal of Clinical Pharmacology
- 1 June 2007
The incidence of nonfatal CAD events decreases when >90% of the prescribed medications is used over at least 1 year, and among patients followed for >1 year, adherence of > or =90% was associated with fewer nonf fatal CAD events.
...
...